Early Response to Ranibizumab Is Predictive of Treatment Demand after a Therapeutic Switch to Aflibercept

After the switch in therapy from ranibizumab to aflibercept, visual acuity remained stable for >12 months in both groups. Nevertheless, eyes that required frequent reinjections under ranibizumab also had a higher treatment demand under aflibercept.